Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Oak vs RedBox Rx

Two GLP-1 desks, one scoreboard. We put Oak and RedBox Rx head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 502 · Grade C

Oak

Visit Oak Full brief →
vs
Higher Brief ScoreNo. 176 · Grade C

RedBox Rx

Visit RedBox Rx Full brief →

The verdict

RedBox Rx takes this head-to-head.

RedBox Rx scores 68 to 43 on our six-factor Brief Score — RedBox Rx is a US telehealth pharmacy (parent company Hy-Vee) offering compounded GLP-1 weight management with flat, dose-independent pricing.

That doesn't make Oak a bad call — it's best for readers weighing oak specifically who want to know what it does and does not publish before handing over 29 questions' worth of medical history — not readers trying to compare a price today. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
38
78
Supply Reliability
44
78
Transparency
34
32
Access Breadth
52
56
Clinical Oversight
44
90
Track Record
50
75
OakBrief Score 43 · 68RedBox Rx

Price, coverage & the tracker

OakRedBox Rx
Brief Score43/100 (C)68/100 (C)
Semaglutide$250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morningFrom $269/mo (all doses, 6-month plan, compounded)
Tirzepatide$300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning$429/mo
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerNewnew to the tracker, no prior readingNewnew to the tracker, no prior reading

Oak: Re-read twice on 15 August 2026 with a real browser and no form input, and the figures MOVED BETWEEN THE TWO READS. In the morning its order form showed $200/mo for compounded semaglutide and $250 for tirzepatide; that afternoon, same URL, same entry path, browser storage cleared as a control, it showed $250 and $300 with the strike-throughs gone and every brand line $100 higher. What is stable is WHERE the price is: on the first screen of its order form, before a single question. The tracker previously carried no figure because the ladder was believed to be behind a 29-question intake — it is not, it is in front of it. What remains true is that Oak advertises nine different "starting" prices at once — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — attaches a term to none, and that its headline "$133 / $199" is the three-month prepay under code OAKSAVE200, billed upfront.

RedBox Rx: New to the tracker on 1 August 2026. The published line reads From $269/mo (all doses, 6-month plan, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.